Revex, Selincro(nalmefene)
Opvee, Selincro (nalmefene) is a small molecule pharmaceutical. Nalmefene was first approved as Revex on 1995-04-17. It is used to treat drug overdose, opioid-related disorders, and respiration disorders in the USA. It has been approved in Europe to treat alcohol-related disorders. The pharmaceutical is active against mu-type opioid receptor and kappa-type opioid receptor. In addition, it is known to target delta-type opioid receptor.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Opvee (generic drugs available since 2022-02-08, discontinued: Revex)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Nalmefene hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| OPVEE | OPIANT PHARMS | N-217470 RX | 2023-05-22 | 1 products, RLD, RS |
Show 1 discontinued
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
32 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Alcoholism | D000437 | EFO_0003829 | F10.1 | 3 | 1 | 6 | 2 | 3 | 15 |
| Resuscitation | D012151 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | — | 1 | — | — | 1 |
| Gambling | D005715 | F63.0 | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pain | D010146 | EFO_0003843 | R52 | 1 | 1 | — | — | 1 | 2 |
| Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | — | 1 | — | — | — | 1 |
| Smoking cessation | D016540 | EFO_0004319 | — | 1 | — | — | — | 1 | |
| Hiv infections | D015658 | EFO_0000764 | B20 | 1 | 1 | — | — | — | 1 |
| Parkinson disease | D010300 | EFO_0002508 | G20 | — | 1 | — | — | — | 1 |
| Impulse control disruptive and conduct disorders | D007174 | F63.2 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pharmacokinetics | D010599 | 2 | — | — | — | — | 2 | ||
| Opioid-related disorders | D009293 | EFO_0005611 | F11 | 2 | — | — | — | — | 2 |
| Renal insufficiency | D051437 | HP_0000083 | N19 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Anesthesia | D000758 | — | — | — | — | 1 | 1 | ||
| Borderline personality disorder | D001883 | HP_0012076 | F60.3 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | NALMEFENE |
| INN | nalmefene |
| Description | Nalmefene is a morphinane alkaloid. |
| Classification | Small molecule |
| Drug class | narcotic agonists/antagonists (normorphine type) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | C=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5 |
Identifiers
| PDB | — |
| CAS-ID | 55096-26-9 |
| RxCUI | 31479 |
| ChEMBL ID | CHEMBL982 |
| ChEBI ID | 7457 |
| PubChem CID | 5284594 |
| DrugBank | DB06230 |
| UNII ID | TOV02TDP9I (ChemIDplus, GSRS) |
Target
Agency Approved
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,245 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
21,323 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more